Frontiers in Endocrinology (Jan 2023)

(Thyroid) Hormonal regulation of breast cancer cells

  • Aleck Hercbergs,
  • Hung-Yun Lin,
  • Shaker A. Mousa,
  • Paul J. Davis

DOI
https://doi.org/10.3389/fendo.2022.1109555
Journal volume & issue
Vol. 13

Abstract

Read online

Thyroid hormone as L-thyroxine (T4) acts nongenomically at physiological concentrations at its cancer cell surface receptor on integrin αvβ3 (‘thyrointegrin’) to cause cancer cell proliferation. In the case of estrogen receptor (ERα)-positive breast cancer cells, T4 via the integrin promotes ERα-dependent cancer growth in the absence of estrogen. Thus, tumor growth in the post-menopausal patient with ERα-positive cancer may again be ER-dependent because of T4. Additional mechanisms by which T4 may contribute uniquely to aggressive breast cancer behavior—independently of ER—are stimulation of immune checkpoint inhibitor gene expression and of several anti-apoptosis mechanisms. These observations may call for consideration of elimination of host T4 production in breast cancer patients whose response is suboptimal to standard chemotherapy regimens. Euthyroidism in such a setting may be maintained with exogenous 3,3’,5-triiodo-L-thyronine (T3).

Keywords